1113 - A Precision Medicine Navigator Can Mitigate Disparities Associated with Utilization of Genomic Tests: A Multi-Institutional Review
Presenter(s)
J. Clark1, H. W. Tseng2, J. H. Chang2, Z. Shamsuddin3, Y. Jack3, A. J. Allen1, C. Datnow-Martinez1, C. Eggleston1, M. J. Ferris1, Z. H. Rana1, S. J. Shah4, M. K. Rooney4, C. Tang4, C. J. Hassanzadeh4, W. F. Regine Jr1, Y. Kwok1, P. T. Tran4, M. A. L. Vyfhuis1, S. Choi4, and J. K. Molitoris1; 1Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, 2MD Anderson Cancer Center, Houston, TX, 3University of Maryland School of Medicine, Baltimore, MD, 4Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Purpose/Objective(s): We have previously demonstrated that a precision medicine navigator (PMN) improves the consistency of standard of care (SOC) genomic testing among prostate cancer patients, most significantly among Black patients, those with lower income and Medicare beneficiaries. We also observed significant improvement in genomic testing utilization at community hospitals. We hypothesized that the presence of a PMN will lead to consistent use of SOC genomic testing utilization among prostate cancer patients across multiple institutions.
Materials/Methods: We performed a retrospective review of prostate cancer consults from two large academic institutions between (2021-2026). We compared the frequency of patients who received SOC genomic testing (Decipher, Tempus or Artera) between institutions following implementation of a PMN.
Results: The sample included 482 patients from institution one (I-1) and 123 patients from institution two (I-2), with median ages 69 and 70 years, respectively. The racial distributions of I-1 and I-2 were 61.2% and 71.5% White, 33.8% and 17.9% Black, 2.9% and 7.3% Asian or Pacific Islander and 1.9% and 3.3% other races. The NCCN risk category distribution for I-1 and I-2 were 9.8% and 0% low risk, 49.8% and 74.8% intermediate risk, and 39.0% and 25.2% high risk, respectively. Patients with SOC genomic testing ordered at I-1 and I-2 after implementation of a PMN was 74.7% (360/482) and 85.37% (105/123).
Conclusion: The addition of a PMN has demonstrated improved consistency of genomic testing, particularly benefiting specific patient subgroups. Additional data from multiple institutions has shown similar high rates of SOC genomic testing utilization with the addition of a PMN. The benefit of PMNs in ensuring consistent SOC genomic testing for prostate cancer warrants further investigation with additional institutional participation.